Biogen Agreement Further Validates Anavex Life Sciences (AVXL) AV2-73 - FBR
- Dow opens at record high led by oil, bank stocks
- Oil tops $55 for first time in 16 months as OPEC deal fuels buying
- Consolidated Communications (CNSL) to Acquire FairPoint Communications (FRP) in $1.5B Deal
- Wall St. stock futures fall after Italy referendum
- Pre-Open Stock Movers 12/05: (FRP) (GMED) (CHK) Higher; (CERC) (HDSN) (MRVL) Lower (more...)
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
FBR Capital analyst Christopher James weighed in on Anavex Life Sciences (NASDAQ: AVXL) after the company announced that it has signed a material transfer agreement with Biogen under which Biogen will test AV2-73 in a validated preclinical CNS assay. As a reminder, AV2-73 is a sigma-1 receptor antagonist with potential to promote recovery of motor function and reactivation of neuroplasticity in patients suffering from neurocognitive diseases.
James commented, "We believe these early studies could lead to its advancement into other neurodegenerative and demyelination diseases such as Parkinson's disease and multiple sclerosis. We view this agreement with BIIB as additional validation for AV2-73's potential in multiple CNS-related disorders, but remain focused on the development plan for the Phase II study with AV2-73 in Rett syndrome, an orphan disease with no approved therapies."
The firm maintained an Outperform rating and price target of $10.00
Shares of Anavex Life Sciences closed at $3.14 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Street Watchdog Research Lowers Price Target on Dollar General (DG) to $55
- UPDATE: BAT Said to Plan Increased Bid for Reynolds American (RAI) as Soon as This Week - Bloomberg
- Jefferies Maintains Bullish View on Ra Pharma (RARX) Following ASH Management Meeting
Create E-mail Alert Related CategoriesAnalyst Comments, FDA, Momentum Movers, Trader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!